Biosimilar biologic drugs: a new frontier in medical care.

about

Policies for biosimilar uptake in Europe: An overview.

P2860

Q47173303-72F2CDF7-396B-4B4D-B165-865A70D88142

P2860

Biosimilar biologic drugs: a new frontier in medical care.

Item

http://www.wikidata.org/entity/Q39200937

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Biosimilar biologic drugs: a new frontier in medical care.

@en

Biosimilar biologic drugs: a new frontier in medical care.

@nl

type

Item

label

Biosimilar biologic drugs: a new frontier in medical care.

@en

Biosimilar biologic drugs: a new frontier in medical care.

@nl

prefLabel

Biosimilar biologic drugs: a new frontier in medical care.

@en

Biosimilar biologic drugs: a new frontier in medical care.

@nl

P1476

Biosimilar biologic drugs: a new frontier in medical care.

@en

P2093

Daniel M Geynisman

http://www.w3.org/2001/XMLSchema#string

Ira Jacobs

http://www.w3.org/2001/XMLSchema#string

K Lea Sewell

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-TNF therapy: past, present and future

Regulatory considerations in oncologic biosimilar drug development

Clinical considerations for the development of biosimilars in oncology

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

Statistical and regulatory considerations in assessments of interchangeability of biological drug products.

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists

What is the future of targeted therapy in rheumatology: biologics or small molecules?

Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

P304

460-470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1311196

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo de Velasco

P577

2017-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28343424

http://www.w3.org/2001/XMLSchema#string

Biosimilar biologic drugs: a new frontier in medical care.

about

P2860

P2860

Biosimilar biologic drugs: a new frontier in medical care.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698